Ajinomoto Co., Ltd.

Yukio Iino

Takashi Yamamoto

Tsuyoshi Kobayashi

Toshihiro Hatanaka

Nobuo Kondo

Takao Ikenoue

Kenji Takehana

Takashi Tsuji

Seiji Niwa

Hiroyuki Matsueda

Yoko Masuzawa

Ryusuke Hirama

Kohichi Fujita

Akiyo Yamazaki

Fumio Ohta

Ariko Kodaira

Koji Ohsumi

Yoko Kageyama

Koichi Fujita

Atsushi Konishi

Makoto Ishii

A pharmaceutical composition for preventing and/or treating diabetes, diabetic complication, hyperinsulinemia, disorders of glucose metabolism or obesity, comprising a combination of the following compound, analogues or pharmaceutically acceptable salts thereof with a hypoglycemic agent. 

Therapeutic agents for diabetes

An agent for increasing the sugar-transporting capacity and an agent for preventing and/or treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which contains a lactam compound or a pharmaceutically acceptable salt thereof as the active ingredient.

Lactam compounds and pharmaceutical use thereof

The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. 

Benzene derivatives and pharmaceutical use thereof

The present invention provides an AP-1 activation inhibitor, a NF-kappaB activation inhibitor, an inflammatory cytokine production inhibitor, a production inhibitor for matrix metalloprotease or an inflammatory cell adhesion factor expression inhibitor, which contains a heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient.

Heterocyclic compounds and medical use thereof

The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention discloses biscyclopropanecarboxamide compounds and pharmaceutically acceptable salts thereof; and also NF-kappa B activation inhibitors, Inflammatory cytokine production inhibitors, matrix metalloprotease production inhibitors, inflammatory cell adhesion molecules incidence inhibitors, antiinflammatory agents, antirheumatic agents, immunosuppressive agents, cancerous metastasis inhibitors or antiviral agents each containing such a compound as the active ingredient.

Biscyclopropanecarboxamide compounds and pharmaceutical use thereof

Anisomycin derivatives represented by the following formula: ##STR1## and salts thereof, wherein R is hydrogen or an acyl group of 1-18 carbon atoms, and X is either a carbamoyl group represented by the formula --CONR.sup.1 R.sup.2 or an alkyl group represented by the formula --CH.sub.2 R.sup.3 in which R.sup.1 and R.sup.2 are each hydrogen, a linear or cyclic alkyl group of 1-6 carbon atoms which may have a substituent or a phenyl group which may have a substituent, and R.sup.3 is hydrogen, an alkyl group of 1-6 carbon atoms or an alkoxy group of 1-6 carbon atoms which may have a substituent, have improved stability in blood or plasma and are useful as anticancer agents, antifungal agents and antiprotozoan agents.

Anisomycin derivatives and anticancer agents, antifungal agents and

Growing community of inventors

Kawasaki, Japan

Yukio Iino